The 21-gene test is limited to lymph node-negative patients with early-stage ER+/PR+, HER2-breast cancer, its prognostic performance in other breast cancer subtypes and in lymph node-positive breast cancers is poorly understood (Poorvu et al., 2020). This evidence concerns the gene ESR1 and breast carcinoma.